Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA
 

Multiple osteochondromas (MO)

Identity

Other namesHereditary multiple exostosis (HME)
Multiple hereditary exostoses (MHE)
Diaphyseal aclasis
Multiple hereditary osteochondromatosis
Multiple cartlaginous exostoses
Inheritance Autosomal dominant disorder, genetically heterogeneous. Males are more often affected, possibly partly due to an incomplete penetrance in females. Approximately 62% of the patients have a positive family history.

Clinics

Phenotype and clinics MO is characterized by the presence of multiple osteochondromas (osteocartilaginous exostosis), i.e. bony protrusions covered by a cartilaginous cap on the outer surface of bone. This results in a variety of orthopaedic deformities such as disproportionate short stature and bowing of the forearm. Osteochondromas are the most common benign bone tumours, representing approximately 50% of all primary benign tumours of bone. They gradually develop and increase in size in the first decade of life. The stratified zones of chondrocytes that are normally found in the growth plate can still be recognised on the interface of cartilage and bone in osteochondroma. Consequently, osteochondromas cease growing as the growth plates close during puberty. The majority of osteochondromas is asymptomatic and is located in bones that developed from cartilage, especially the long bones in the extremities. Patients with an 1 mutation have a more severe phenotype than patients with an 2 mutation.
Neoplastic risk Malignant transformation is low in solitary osteochondromas (<1%) but is estimated to occur in 0.5-5% of cases of multiple osteochondromas (MO).
Treatment Osteochondromas can be surgically removed for cosmetic or functional reasons.

Cytogenetics

Cytogenetics of cancer Clonal karyotypic abnormalities in the cartilaginous cap of osteochondroma involving 8q22-24.1 were found in ten out of 30 sporadic and in 1 out of 13 multiple osteochondromas, supporting a neoplastic origin. This was confirmed since aneuploidy was found in 4 out of 10 osteochondromas and LOH was almost exclusively found at the 1 locus in 5 out of 14 osteochondromas. Aberrations of chromosome 1p (1p13-p22) were found in five of seven osteochondromas.

Genes involved and Proteins

Note MO is a genetically heterogeneous disorder for which at present, two genes, 1 and 2 located respectively on 8q24 and 11p11-p12, have been isolated. The EXT1 gene was reported to show linkage in 44%-66% of the MO families, whereas EXT2 would be involved in 27%.
Additional linkage to chromosome 19p has been found, suggesting the existence of an 3 -gene, although loss of heterozygosity studies could not confirm this and the gene has not been identified so far. Two patients with MO demonstrated a germline mutation in 1 combined with loss of the remaining wild type allele in three osteochondromas, confirming the tumour suppressor function of the EXT genes and indicating that in cartilaginous cells of the growth plate inactivation of both copies of the EXT1-gene is required for osteochondroma formation in hereditary cases. Homozygous deletions of EXT1 identified in seven out of eight non-hereditary osteochondromas further support the two hit model. However, loss of the remaining wildtype allele can be demonstrated in only a subset of osteochondromas in MO patients.
 
Gene Name1 (exostosin-1)
Location 8q24
DNA/RNA
Description The 1 gene is composed of 11 exons, and the 2 gene consists of 16 exons.
Protein
Expression Both 1 and 2 mRNA is ubiquitously expressed. A high level of expression of EXT1 and EXT2 mRNA has been found in developing limb buds of mouse embryos and expression was demonstrated to be confined to the proliferating and prehypertrophic chondrocytes of the growth plate.
Function A tumour suppressor function is suggested for the genes. The gene products, exostosin-1 (1) and exostosin-2 (EXT2), are endoplasmic reticulum localized type II transmembrane glycoproteins which form a Golgi-localized hetero-oligomeric complex that catalyzes heparan sulphate (HS) polymerization. Heparan sulphate proteoglycans (HSPG) are large macromolecules composed of heparan sulphate glycosaminoglycan chains linked to a protein core. Four HSPG families are syndecan, glypican, perlecan and isoforms of CD44. HSPGs are required for high-affinity binding of fibroblast growth factor to its receptor. Furthermore, studies in Drosophila have shown that EXT (tout-velu, Ttv) is required for the diffusion of the morphogens: Hedgehog (Hh, human homologues Indian Hedgehog (IHh) and Sonic Hedgehog (SHh), decapentaplegic (dpp, human homologues TGF-beta and BMP) and wingless (human homologue Wnt). It was therefore hypothesized that EXT mutations affect IHh / PTHLH, TGF-beta/BMP and Wnt signaling pathways within the normal growth plate. Indeed, altered levels of the EXT1 and EXT2 protein and of their putative downstream effectors (IHh/PTHrP, TGF-beta/BMP and Wnt signalling pathways) were demonstrated in both sporadic and hereditary osteochondroma. In addition, due to impaired EXT1/EXT2 function the HSPGs appear to be retained in the Golgi apparatus and cytoplasm of the tumour cell, instead of being transported to the cell surface and/or extra cellular matrix where they normally exert their function. Moreover, EXT mutations were described to induce cytoskeletal abnormalities (altered actin distribution) in osteochondroma chondrocytes.
Mutations
Germinal Germline mutations of 1 and 2 in MO patients have been studied extensively in Caucasian as well as Asian populations.
Somatic One sporadic osteochondroma was described to harbour a deletion of one 1 gene combined with an inactivating mutation in the other 1 gene. No somatic mutations were found in the EXT1 and EXT2 gene in 34 sporadic and hereditary osteochondromas and secondary peripheral chondrosarcomas tested.

 
Gene Name2 (exostosin-2)
Location 11p11-p12

External links

OrphanetExostoses, multiple

Bibliography

Hereditary multiple exostoses; report of a family.
Crandall BF, Field LL, Sparkes RS, Spence MA.
Clin Orthop Relat Res. 1984 Nov;(190):217-9.
PMID 6333306
 
Genetic heterogeneity in families with hereditary multiple exostoses.
Cook A, Raskind W, Blanton SH, Pauli RM, Gregg RG, Francomano CA, Puffenberger E, Conrad EU, Schmale G, Schellenberg G, et al.
Am J Hum Genet. 1993 Jul;53(1):71-9.
PMID 8317501
 
A gene for hereditary multiple exostoses maps to chromosome 19p.
Le Merrer M, Legeai-Mallet L, Jeannin PM, Horsthemke B, Schinzel A, Plauchu H, Toutain A, Achard F, Munnich A, Maroteaux P.
Hum Mol Genet. 1994 May;3(5):717-22.
PMID 8081357
 
Cloning of the putative tumour suppressor gene for hereditary multiple exostoses (1).
Ahn J, Ludecke H, Lindow S, Horton WA, Lee B, Wagner MJ, Horsthemke B, Wells DE.
Nat Genet. 1995 Oct;11(2):137-43.
PMID 7550340
 
Natural history study of hereditary multiple exostoses.
Wicklund LC, Pauli RM, Johnston D, Hecht JT.
Am J Med Genet. 1995 Jan 2;55(1):43-6.
PMID 7702095
 
The 2 multiple exostoses gene defines a family of putative tumour suppressor genes.
Stickens D, Clines G, Burbee D, Ramos P, Thomas S, Hogue D, Hecht JT, Lovett M, Evans GA.
Nat Genet. 1996 Sep;14(1):25-32.
PMID 8782816
 
Positional cloning of a gene involved in hereditary multiple exostoses.
Wuyts W, Van Hul W, Wauters J, Nemtsova M, Reyniers E, Van Hul E, De Boulle K, De Vries BBA, Hendrickx J, Herrygers I, et al.
Hum Mol Genet. 1996 Oct;5(10):1547-57.
PMID 8894688
 
Hereditary multiple exostoses (): mutational studies of familial 1 cases and EXT-associated malignancies.
Hecht JT, Hogue D, Wang Y, Blanton SH, Wagner M, Strong LC, Raskind W, Hansen MF, Wells D.
Am J Hum Genet. 1997 Jan;60(1):80-6.
PMID 8981950
 
An extension of the admixture test for the study of genetic heterogeneity in hereditary multiple exostoses.
Legeai-Mallet L, Margaritte-Jeannin P, Lemdani M, Le Merrer M, Plauchu H, Maroteaux P, Munnich A, Clerget-Darpoux F.
Hum Genet. 1997 Mar;99(3):298-302.
PMID 9050912
 
Incomplete penetrance and expressivity skewing in hereditary multiple exostoses.
Legeai-Mallet L, Munnich A, Maroteaux P, Le Merrer M.
Clin Genet. 1997 Jul;52(1):12-6.
PMID 9272707
 
Mutation screening of the 1 and 2 genes in patients with hereditary multiple exostoses.
Philippe C, Porter DE, Emerton ME, Wells DE, Simpson AH, Monaco AP.
Am J Hum Genet. 1997 Sep;61(3):520-8.
PMID 9326317
 
Tout-velu is a Drosophila homologue of the putative tumour suppressor -1 and is needed for Hh diffusion.
Bellaiche Y, The I, Perrimon N.
Nature 1998 Jul 2;394(6688):85-8.
PMID 9665133
 
Evaluation of locus heterogeneity and 1 mutations in 34 families with hereditary multiple exostoses.
Raskind WH, Conrad EU 3rd, Matsushita M, Wijsman EM, Wells DE, Chapman N, Sandell LJ, Wagner M, Houck J.
Hum Mutat. 1998;11(3):231-9.
PMID 9521425
 
Mutations in the 1 and 2 genes in hereditary multiple exostoses.
Wuyts W, Van Hul W, De Boulle K, Hendrickx J, Bakker E, Vanhoenacker F, Mollica F, Ludecke H, Sitki Sayli B, Pazzaglia UE, et al.
Am J Hum Genet. 1998 Feb;62(2):346-54.
PMID 9463333
 
-mutation analysis and loss of heterozygosity in sporadic and hereditary osteochondromas and secondary chondrosarcomas.
Bovee JVMG, Cleton-Jansen AM, Wuyts W, Caethoven G, Taminiau AHM, Bakker E, Van Hul W, Cornelisse CJ, Hogendoorn PCW.
Am J Hum Genet. 1999 Sep;65(3):689-98.
PMID 10441575
 
Germline mutations in the 1 and 2 genes in Korean patients with hereditary multiple exostoses.
Park KJ, Shin K, Ku J, Cho T, Lee SH, Choi IH, Phillipe C, Monaco AP, Porter DE, Park J
J Hum Genet. 1999;44(4):230-4.
PMID 10429361
 
Mutation analysis of hereditary multiple exostoses in the Chinese.
Xu L, Xia J, Jiang H, Zhou J, Li H, Wang D, Pan Q, Long Z, Fan C, Deng H.
Hum Genet. 1999 Jul-Aug;105(1-2):45-50.
PMID 10480354
 
Cytoskeletal abnormalities in chondrocytes with 1 and 2 mutations.
Bernard MA, Hogue DA, Cole WG, Sanford T, Snuggs MB et al.
J Bone Miner Res. 2000 Mar;15(3):442-50.
PMID 10750558
 
Up-regulation of PTHrP and Bcl-2 expression characterizes the progression of osteochondroma towards peripheral chondrosarcoma and is a late event in central chondrosarcoma.
Bovée JV, van den Broek LJ, Cleton-Jansen AM, Hogendoorn PC.
Lab Invest. 2000 Dec;80(12):1925-34.
PMID 11140704
 
1 gene mutation induces chondrocyte cytoskeletal abnormalities and defective collagen expression in the exostoses.
Legeai-Mallet L, Rossi A, Benoist-Lasselin C, Piazza R, Mallet JF et al.
J Bone Miner Res. 2000 Aug;15(8):1489-500.
PMID 10934647
 
Clinical and radiographic analysis of osteochondromas and growth disturbance in hereditary multiple exostoses.
Porter DE, Emerton ME, Villanueva-Lopez F, Simpson AH.
J Pediatr Orthop. 2000 Mar-Apr;20(2):246-50.
PMID 10739291
 
Diminished levels of the putative tumor suppressor proteins 1 and 2 in exostosis chondrocytes.
Bernard MA, Hall CE, Hogue DA, Cole WG, Scott A, Snuggs MB et al.
Cell Motil Cytoskeleton. 2001 Feb;48(2):149-62.
PMID 11169766
 
Multiple osteochondromas.
Bovée JV, Hogendoorn PC.
In: World Health Organization classification of tumours. Pathology and genetics of tumours of soft tissue and bone, Editors: Fletcher CD, Unni KK, Mertens F, IARC Press, Lyon, 2002, 360-362.
 
Cytogenetic and molecular cytogenetic evidence of recurrent 8q24.1 loss in osteochondroma.
Feely MG, Boehm AK, Bridge RS, Krallman PA, Neff JR, et al.
Cancer Genet Cytogenet. 2002 Sep;137(2):102-7.
PMID 12393280
 
Reevaluation of a genetic model for the development of exostosis in hereditary multiple exostosis.
Hall CR, Cole WG, Haynes R, Hecht JT.
Am J Med Genet. 2002 Sep 15;112(1):1-5.
PMID 12239711
 
Osteochondroma.
Khurana J, Mertens F, Bovée JV.
In: World Health Organization classification of tumours. Pathology and genetics of tumours of soft tissue and bone, Editors: Fletcher CD, Unni KK, Mertens F, IARC Press, Lyon, 2002, 234-236.
 
Recurring breakpoints of 1p13 approximately p22 in osteochondroma.
Sawyer JR, Thomas EL, Lukacs JL, Swanson CM, Ding Y, Parham DM, Thomas JR, Nicholas RW.
Cancer Genet Cytogenet. 2002 Oct 15;138(2):102-6.
PMID 12505252
 
Abrogation of heparan sulfate synthesis in Drosophila disrupts the Wingless, Hedgehog and Decapentaplegic signaling pathways.
Bornemann DJ, Duncan JE, Staatz W, Selleck S, Warrior R.
Development 2004 May;131(9):1927-38.
PMID 15056609
 
Multiple osteochondromas: clinicopathological and genetic spectrum and suggestions for clinical management.
Hameetman L, Bovée JV, Taminiau AH, Kroon, HM, Hogendoorn PC.
Hereditary Cancer in Clinical Practice (2004); 2 (4) 161-173.
 
Distinct and collaborative roles of Drosophila family proteins in morphogen signalling and gradient formation.
Han C, Belenkaya TY, Khodoun M, Tauchi M, Lin X, Lin X.
Development 2004 Apr;131(7):1563-75.
PMID 14998928
 
Severity of disease and risk of malignant change in hereditary multiple exostoses. A genotype-phenotype study.
Porter DE, Lonie L, Fraser M, Dobson-Stone C, Porter JR et al.
J Bone Joint Surg Br. 2004 Sep;86(7):1041-6.
PMID 15446535
 
The genotype-phenotype correlation of hereditary multiple exostoses.
Alvarez C, Tredwell S, De Vera M, Hayden M.
Clin Genet. 2006 Aug;70(2):122-30.
PMID 16879194
 
Peripheral chondrosarcoma progression is accompanied by decreased Indian Hedgehog signalling.
Hameetman L, Rozeman LB, Lombaerts M, Oosting J, Taminiau AH, Cleton-Jansen AM, Bovée JV, Hogendoorn PC.
J Pathol. 2006 Aug;209(4):501-11.
PMID 16755518
 
Evaluation of the anatomic burden of patients with hereditary multiple exostoses.
Alvarez CM, De Vera MA, Heslip TR, Casey B
Clin Orthop Relat Res. 2007 Sep;462:73-9.
PMID 17589361
 
Decreased expression and intracellular accumulation of heparan sulphate proteoglycan in osteochondromas and peripheral chondrosarcomas.
Hameetman L, David G, Yavas A, White SJ, Taminiau AH, et al.
J Pathol. 2007 Mar;211(4):399-409.
PMID 17226760
 
The role of 1 in nonhereditary osteochondroma: identification of homozygous deletions.
Hameetman L, Szuhai K, Yavas A, Knijnenburg J, van Duin M, van Dekken H et al.
J Natl Cancer Inst 2007 Mar 7: 99(5):396-406.
PMID 17341731
 
Clinical outcome and genotype in patients with hereditary multiple exostoses.
Jager M, Westhoff B, Portier S, Leube B, Hardt K, et al.
J Orthop Res. 2007 Dec;25(12):1541-51.
PMID 17676624
 
Multiple osteochondromas.
Bovée JV
Orphanet J Rare Dis. 2008 Feb 13;3:3. Review
PMID 18271966
 
REVIEW articlesautomatic search in PubMed
Last year articlesautomatic search in PubMed

Contributor(s)

Written01-2000Judith VMG Bovée
Updated03-2002Judith VMG Bovée
Updated07-2008Christianne MA Reijnders, Judith VMG Bovée

Citation

This paper should be referenced as such :
Reijnders, CMA ; Bovée, JVMG
Multiple osteochondromas (MO)
Atlas Genet Cytogenet Oncol Haematol. 2009;13(8):605-607.
Free online version   Free pdf version   [Bibliographic record ]
History of this paper:
Bovée, JVMG. Hereditary multiple exostoses (HME). Atlas Genet Cytogenet Oncol Haematol. 2002;6(3):239-241.
http://documents.irevues.inist.fr/bitstream/2042/37885/1/03-2002-HeredMultExostosID10061.pdf
Reijnders, CMA ; Bovée, JVMG. Multiple osteochondromas (MO). Atlas Genet Cytogenet Oncol Haematol. 2009;13(8):605-607.
http://documents.irevues.inist.fr/bitstream/2042/44546/1/07-2008-HeredMultExostosID10061.pdf
URL : http://AtlasGeneticsOncology.org/Kprones/HeredMultExostosID10061.html

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Wed Jul 30 15:02:10 CEST 2014


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.